Last reviewed · How we verify
Visanne
At a glance
| Generic name | Visanne |
|---|---|
| Also known as | Dienogest |
| Sponsor | Mansoura University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis
- Clinical Study to Compare Efficacy and Safety of Indinol Forto® 200 mg Capsules and Visanne 2 mg Tablets in Treatment of Endometriosis (PHASE3)
- Salivary microRNA in Endometriosis: Correlation With Response to Progestin Therapy
- A Study to Learn More About How Safe Dienogest is and How Well it Works Under Real World Conditions in Indian Women With Endometriosis
- Role of Medical Treatment in Endometriosis Patients Undergoing ICSI (NA)
- A Study to Learn More About Using Dienogest to Treat Endometriosis in Chinese Participants
- The Effect of Dienogest vs. Norethindrone Acetate Treatment in Endometriosis (NA)
- Synthetic vs Natural Estrogen in Combined Oral Contraception (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Visanne CI brief — competitive landscape report
- Visanne updates RSS · CI watch RSS
- Mansoura University portfolio CI